RxDoctor Payments Data

Shawn Lazoff, DO

Family Medicine · Summerfield, NCNPI 1982993309

Payments from drug & device makers

$627in general payments, 2019–2025

Across 24 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$191
  • AstraZeneca$148
  • AbbVie$92
  • Pfizer$87
  • Johnson & Johnson$31
  • GSK$24
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$61298%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$627 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$41,376
Medicare patients
127
Services billed
1,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$34,050
MounjaroTirzepatide31$32,044
JanuviaSitagliptin Phosphate27$27,245
JardianceEmpagliflozin25$23,640
XareltoRivaroxaban23$20,694
Breo ElliptaFluticasone/Vilanterol23$13,287
EliquisApixaban16$12,147
MyrbetriqMirabegron12$11,434
DuleraMometasone/Formoterol13$4,752
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,869
Rosuvastatin Calcium217$3,607
Albuterol Sulfate HfaAlbuterol Sulfate64$2,084
Gabapentin93$1,794
Amlodipine Besylate216$1,722
Atorvastatin Calcium146$1,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$191$34,05027 claims
Lilly USA, LLCMounjaro$12$32,04431 claims
MerckJanuvia, Dulera$11$31,99740 claims
Boehringer IngelheimJardiance$15$23,64025 claims
Johnson & JohnsonXarelto$31$20,69423 claims
GSKBreo Ellipta$24$13,28723 claims
PfizerEliquis$87$12,14716 claims
AbbVieSynthroid$92$1,17618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Summerfield

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →